Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Progressive Resistance Training Versus Total Hip Arthroplasty in Patients With Hip Osteoarthritis

NCT04070027 · tracked via the Priya Life Science Denmark tracker
Phase
Not applicable
Started
2019-09-02
Last updated
2026-08-21

Condition(s) studied

Hip Osteoarthritis

Investigational drug(s) / intervention(s)

Total Hip ArthroplastyProgressive Resistance Training

Total Hip Arthroplasty: Total hip arthroplasty following standard procedures.

Progressive Resistance Training: Progressive resistance training based on available evidence on patients with hip osteoarthritis and designed in accordance with the "American College of Sports Medicine" (ACSM) recommendations for progression models in resistance training aiming at inducing muscle hypertrophy and increasing muscle strength and power.

Study summary

Hip osteoarthritis is associated with joint pain, physical disability, decreased muscle strength and poor health status, and the most common cause for total hip arthroplasty. No studies have investigated the effect of total hip arthroplasty compared to non-surgical treatment in patients with end-stage hip osteoarthritis. This comparison is of upmost importance as it is unknown whether non-surgical treatment may be used as an alternate to surgery.

The purpose of this study is to investigate whether total hip arthroplasty followed by standard care is superior to progressive resistance training for improving hip function and pain in patients with end-stage hip osteoarthritis.

The hypothesis is that patients treated with total hip arthroplasty will improve more than patients treated with progressive resistance training.

Eligibility

Sex
ALL
Min age
50 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Adults aged ≥50 years 2. Clinical history and symptoms consistent with primary hip osteoarthritis (including hip osteoarthritis due to mild hip dysplasia that may be treated with standard components) and radiographic verified hip osteoarthritis defined as joint space narrowing \<2 mm 3. Considered eligible for total hip arthroplasty by an orthopaedic surgeon (i.e. duration of symptoms \>3 months, hip related pain, functional impairment or decreased range of motion (ROM), and attempted treatment with analgesics) Exclusion Criteria: 1. Severe walking deficits (dependency of two crutches or walker) 2. Body Mass Index \>35 kg/m2 3. Lower extremity fractures within one-year prior to inclusion 4. Planned other lower extremity surgery within six months 5. Cancer diagnosis and receiving chemo-, immuno- or radiotherapy 6. Neurological diseases (e.g. previous stroke, multiple sclerosis, Parkinson's, Alzheimer's). 7. Other reasons for exclusion (i.e. inadequacy in written and spoken Danish, mentally unable to participate, physically unable to comply with the PRT protocol due to comorbidity (e.g. severe heart disease, previous major lower extremity surgery within six-months) etc.).

Primary outcome measure(s)

  • Change in the Oxford Hip Score (OHS) from baseline to 6 months — 6 months
    The OHS is a 12-item patient-reported outcome measure designed to assess hip function and pain within the last four weeks among patients suffering from hip osteoarthritis in one score. The total score ranges from 0 to 48, with higher scores indicating better disease status.

Trial sites (4)

FacilityCityRegionStatus
Department of Orthopaedic Surgery, Aarhus University Hospital (AUH) Aarhus Denmark
Department of Orthopaedic Surgery, Naestved Hospital Næstved Denmark
Department of Orthopaedic Surgery and Traumatology, Odense University Hospital (OUH) Odense Denmark
Depatment of Orthopaedic Surgery, Vejle Hospital Vejle Denmark
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04070027 on ClinicalTrials.gov ↗ ← All trials in Denmark